stockrowFortrea Holdings Inc.
FTRE Healthcare Biotechnology
Fortrea Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 1.00% from fiscal 2024.
- Revenue
- −1.40%
- EPS
- +103.7%
- Free cash flow
- −34.0%
- Total debt
- −6.33%
Quarter to September 2026, against a year earlier
Follow FTRE
Alert me
Fortrea Holdings Inc. (FTRE) Free cash flow
Fortrea Holdings Inc.'s free cash flow for fiscal 2025 was $88.3M, down 62.9% from $237.8M in fiscal 2024. Over the twelve months to 30 September 2026 it was $171.0M. Over the past ten years it has ranged from $28.7M (fiscal 2022) to $237.8M (fiscal 2024); the current reading is higher than 33% of that period. Fortrea Holdings Inc. ranks 22nd of 603 Biotechnology companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $88.3M | (62.87%) |
| FY2024 | $237.8M | 74.08% |
| FY2023 | $136.6M | 375.96% |
| FY2022 | $28.7M | (80.01%) |
| FY2021 | $143.6M | (28.52%) |
| FY2020 | $200.9M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Sep 2026 | $52.5M | 139.73% |
| Jun 2026 | $21.9M | — |
| Mar 2026 | −$25.0M | — |
| Dec 2025 | $121.6M | 52.96% |
| 15 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| HRMY Harmony Biosciences Holdings, Inc. compare | $323.0M |
| SRPT Sarepta Therapeutics, Inc. compare | $176.4M |
| FTRE Fortrea Holdings Inc. | $171.0M |
| TRAX First Tracks Biotherapeutics, Inc. compare | −$112.3M |
| ZYME Zymeworks Inc. compare | −$120.5M |
| VIR Vir Biotechnology, Inc. compare | −$141.9M |
| IMNM Immunome, Inc. compare | −$219.1M |
| REPL Replimune Group, Inc. compare | −$245.7M |
| BHVN Biohaven Ltd. compare | −$473.2M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)